论文部分内容阅读
目的:观察哮喘患儿血骨源性碱性磷酸酶(BALP)、钙及磷的表达水平,探讨舒利迭吸入治疗对人体骨骼发育的影响。方法:43例哮喘患儿,连续3个月每天2次给予吸入舒利迭(每包含沙美特罗50μg和氟替卡松100μg)干粉制剂准纳器,每次一包。分别检测治疗前、后血BALP、钙及磷的表达水平。结果:与治疗前相比,治疗后血BALP、钙及磷的表达水平差异均无显著性(P>0.05)。结论:连续3个月每天吸入舒利迭(含200μg的丙酸氟替卡松),没有显著影响儿童骨骼的发育,认为舒利迭临床上使用较为安全。
Objective: To observe the expression of blood alkaline phosphatase (BALP), calcium and phosphorus in asthmatic children and to explore the effect of seretide inhalation on skeletal development in human. METHODS: Forty-three children with asthma were given asthma inhalers (each containing 50 mg of salmeterol and 100 μg of fluticasone) for 2 consecutive days per day for 3 weeks. The levels of BALP, calcium and phosphorus were measured before and after treatment respectively. Results: Compared with before treatment, there was no significant difference in the levels of serum BALP, calcium and phosphorus after treatment (P> 0.05). CONCLUSIONS: Seretide (containing 200 μg fluticasone propionate) per day for 3 consecutive months did not significantly affect skeletal development in children, suggesting that seretide is safer to use clinically.